Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects

American Journal of Kidney Diseases

Volumn 30, Issue 5, 1997, Pages 659-664

  Cannella, Giuseppe ^a,b   Paoletti, Ernesto ^a   Delfino, Roberto ^a   Peloso, Giancarlo ^a   Rolla, Davide ^a   Molinari, Sandra ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Div di Nefrologia e Dialisi M9   (Italy)

Author keywords

ACE inhibitors; Chronic uremia; Dialysis; Left ventricular hypertrophy

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE; UREMIA;

EID: 0030725787     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90490-X     Document Type: Article

References (24)

1. London GM, Fabiani F: Left ventricular dysfunction in end-stage renal disease. Echocardiographic insights, in Parfrey PS, Harnett JD (eds): Cardiac Dysfunction in Chronic Uremia. Basel, Switzerland, Kluwer Academic, 1992, pp 117-137
2. Rambausek M, Ritz E, Mall G, Mehls O, Katus H: Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 28:775-782, 1985
3. Cannella G, Paoletti E, Delfino R, Peloso GC, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 44:881-886, 1993
4. Cruickshank JM, Lewis J, Moore V, Dodd C: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 6:85-90, 1992
5. Sargent JA, Gotch FA: Mathematic modeling of dialysis therapy. Kidney Int 18:S2-S11, 1980
6. O'Rourke RA, Manrath P, Henry WN, Hugenholtz PG, Pisa Z, Roelandt J, Tanaka M: Report of the joint International Society and Federation of Cardiology/World Health Organization task force: Recommendations for standardization of measurements from M-mode echocardiograms. Circulation 69:854A-857A, 1984
7. Cannella G, LaCanna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 6:31-37, 1991
8. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparisons to necropsy findings. Am J Cardiol 57:450-458, 1986
9. Lowrie EG, Teehan BP: Principles of prescribing dialysis therapy: Implementing recommendations from the National Cooperative Dialysis Study. Kidney Int 23:S113-S122, 1983
10. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD: Left ventricular hypertrophy in end stage renal disease. Nephron 48:107-115, 1988
11. Raab W, Burlington VT: Cardiotoxic substances in the blood and heart muscle in uremia. (Their nature and action.) J Lab Clin Med 29:715-734, 1944
12. Mall G, Hunter W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5:39-44, 1990
13. Weber KT, Brilla CG: Pathophysiology of left ventricular hypertrophy, in Cruickshank KJM, Messerli FH (eds): Left Ventricular Hypertrophy and Its Regression. London, UK, Science, 1992, pp 21-29
14. Dzau VJ: Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153:937-942, 1993
15. Frolich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Schub C: The heart in hypertension. N Engl J Med 327:998-1008, 1992
16. Linz W, Scholkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 11:1325-1350, 1989
17. May RC, Mitch W: Pathophysiology of uremia, in Brenner BM (ed): Brenner and Rector's The Kidney. Philadelphia, PA, Saunders, 1996, pp 2148-2169
18. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
19. Suzuki H, Schaefer L, Ling H, Schaefer RM, Dammrich J, Teschner M, Heidland A: Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: Potential roles of lysosomal proteinases. Am J Nephrol 15:129-136, 1995
20. Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB: Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 22:1873-1880, 1993
21. Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM: Wave reflections and cardiac hypertrophy in chronic uremia: influence of body size. Hypertension 22:876-883, 1993
22. Roithinger FX, Punzengruber C, Wallner M, Ulbrich W, Pachinger O, Kramar R, Prischl FC: The influence of ACE-inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. Clin Nephrol 42:309-314, 1994
23. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989
24. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS: Risk factors for development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 4:1486-1490, 1994